Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase
- 18 February 2008
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 260 (1-2), 127-136
- https://doi.org/10.1016/j.canlet.2007.10.023
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxideProceedings of the National Academy of Sciences of the United States of America, 2007
- Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivoToxicology and Applied Pharmacology, 2007
- Thioredoxin reductase as a novel molecular target for cancer therapyCancer Letters, 2006
- Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma CellsJournal of Biological Chemistry, 2006
- Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compoundsFree Radical Biology & Medicine, 2005
- The thioredoxin system—From science to clinicMedicinal Research Reviews, 2003
- Active sites of thioredoxin reductases: Why selenoproteins?Proceedings of the National Academy of Sciences of the United States of America, 2003
- Physiological functions of thioredoxin and thioredoxin reductaseJBIC Journal of Biological Inorganic Chemistry, 2000
- Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene.Proceedings of the National Academy of Sciences of the United States of America, 1996
- A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity.Proceedings of the National Academy of Sciences of the United States of America, 1996